The global Victoza market is estimated to be valued at USD 647.3 Mn in 2025 and is expected to decline to USD 172.6 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -17.2% from 2025 to 2032.
The global Victoza market, a key segment within the pharmaceutical industry, focuses on managing type 2 diabetes mellitus with Victoza (liraglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. Initially, the drug gained significant traction due to its efficacy in glycemic control and potential cardiovascular benefits. However, the market is now experiencing slower growth, marked by a negative compound annual growth rate (CAGR). This is primarily driven by increasing competition from generic alternatives and newer GLP-1 receptor agonists that offer improved efficacy profiles, along with healthcare cost constraints influencing treatment choices.
Although the global prevalence of diabetes continues to rise, creating ongoing demand for effective therapeutic interventions, the market for Victoza is facing pressures from market saturation and pricing competition. The emergence of more cost-effective alternatives and treatment options with enhanced outcomes has affected Victoza’s position. As such, while Victoza remains an important treatment option, its growth is now subdued, and the market is evolving with newer therapies gaining traction in the diabetes management landscape.
Market Dynamics
The global Victoza market is facing a slower growth trajectory, driven by the escalating global prevalence of type 2 diabetes. However, the market’s growth is being tempered by increased competition from generic alternatives and new GLP-1 receptor agonists with better efficacy profiles. While Victoza has proven cardiovascular benefits and is a cornerstone in treatment guidelines, its high cost and patent expiration concerns have limited its expansion, particularly in price-sensitive markets and among uninsured patients.
The market faces significant constraints, including affordability challenges and the introduction of biosimilars that threaten market exclusivity. Moreover, potential side effects, such as gastrointestinal issues and rare cases of pancreatitis, are affecting patient acceptance and physician prescribing patterns. Despite these challenges, there are still opportunities in emerging markets such as Asia Pacific, Latin America, and Africa, where healthcare infrastructure is improving and diabetes awareness is rising. The development of combination therapies and potential expansions into obesity management could further mitigate market slowdown and open new revenue streams for Victoza, though these opportunities may not be sufficient to reverse the overall decline in market growth.
Key Features of the Study
Market Segmentation
Table of Contents
*Browse 32 market data tables and 28 figures on ‘Victoza Market' - Global forecast to 2032
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
